Virtu Financial LLC Makes New $616,000 Investment in Insulet Co. (NASDAQ:PODD)

Virtu Financial LLC purchased a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,648 shares of the medical instruments supplier's stock, valued at approximately $616,000.

Several other large investors also recently bought and sold shares of PODD. Integrated Wealth Concepts LLC grew its position in shares of Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock worth $596,000 after buying an additional 42 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock valued at $484,000 after acquiring an additional 47 shares during the last quarter. Wedmont Private Capital grew its holdings in Insulet by 3.5% during the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier's stock worth $326,000 after acquiring an additional 48 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd increased its position in shares of Insulet by 4.7% in the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier's stock worth $250,000 after purchasing an additional 48 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its stake in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after purchasing an additional 56 shares in the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research reports. Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. Barclays raised their target price on Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Morgan Stanley upped their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research report on Monday, November 11th. Citigroup increased their price objective on shares of Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Canaccord Genuity Group upped their target price on shares of Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $267.44.

Insulet Stock Down 0.9 %

Insulet stock traded down $2.39 during mid-day trading on Friday, reaching $269.34. The company's stock had a trading volume of 571,633 shares, compared to its average volume of 762,207. The company has a market capitalization of $18.89 billion, a price-to-earnings ratio of 46.12, a price-to-earnings-growth ratio of 4.18 and a beta of 1.21. The business's 50 day simple moving average is $251.37 and its 200 day simple moving average is $220.31. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.77.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the company's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.47% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.